tiprankstipranks
LadRx (LADX)
OTHER OTC:LADX
US Market

LadRx (LADX) Stock Price & Analysis

371 Followers

LADX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.61 - $17.70
Previous Close$2.32
Volume307.00
Average Volume (3M)959.00
Market Cap
$1.15M
Enterprise Value-$887.86K
Total Cash (Recent Filing)$2.07M
Total Debt (Recent Filing)$33.61K
Price to Earnings (P/E)>-0.1
Beta0.22
May 08, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-245.03
Shares Outstanding495,092
10 Day Avg. Volume430
30 Day Avg. Volume959
Standard Deviation0.37
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)11.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

LADX FAQ

What was LadRx’s price range in the past 12 months?
LadRx lowest stock price was $0.61 and its highest was $17.70 in the past 12 months.
    What is LadRx’s market cap?
    Currently, no data Available
    When is LadRx’s upcoming earnings report date?
    LadRx’s upcoming earnings report date is May 08, 2024 which is in 6 days.
      How were LadRx’s earnings last quarter?
      LadRx released its earnings results on May 10, 2023. The company reported -$248.1 earnings per share for the quarter, missing the consensus estimate of N/A by -$248.1.
        Is LadRx overvalued?
        According to Wall Street analysts LadRx’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does LadRx pay dividends?
          LadRx does not currently pay dividends.
          What is LadRx’s EPS estimate?
          LadRx’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does LadRx have?
          LadRx has 495,092 shares outstanding.
            What happened to LadRx’s price movement after its last earnings report?
            LadRx reported an EPS of -$248.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.738%.
              Which hedge fund is a major shareholder of LadRx?
              Currently, no hedge funds are holding shares in LADX
              ---

              LadRx Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              LadRx

              CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Cormedix
              Genetic Technologies
              Inovio Pharmaceuticals
              Moderna
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis